Navigation Links
Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
Date:7/22/2009

PHILADELPHIA, July 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse(R)( )(lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last time point assessed (13 hours) after administration.( ) In this pediatric analog classroom study, treatment with Vyvanse was associated with significant improvement in behavior and attention in children at each time point measured, with improvement at 13 hours after administration.( )

"Pediatric patients may require ADHD symptom improvement both at school and after school,"( )said Sharon Wigal, PhD, lead investigator of the study, clinical professor of pediatrics and director of clinical trials in the Child Development Center at the University of California, Irvine. "These published data are the first to have shown duration of effect of an oral ADHD stimulant in children aged 6 to 12 at 13 hours after administration. Physicians and caregivers who are seeking a long-acting medication that provides ADHD symptom improvement from morning through homework and family time may want to consider this Vyvanse study data."( )

On May 22, 2009, the US Food and Drug Administration (FDA) approved a change to the prescribing information for Vyvanse to include supplemental data that demonstrated significant ADHD symptom improvement in children aged 6 to 12 from the first time point measured (1.5 hours) up to 13 hours postdose. Vyvanse is now the first and only oral ADHD stimulan
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... WASHINGTON , Aug. 26, 2014 ... Next Generation Dx Summit; Moving Assays to ... "Targeted Detection and Monitoring of Cell Free Tumor ... the analytical component of its Precision Cancer Monitoring ... high clinical sensitivity for the detection of tumor ...
(Date:8/26/2014)... 2014  Guardant Health, a healthcare company focused ... products, has been recognized today by the World ... . As an innovator in non-invasive, tumor profiling, ... a wide variety of industries and regions to ... ® , Guardant Health,s first commercially available product, ...
(Date:8/26/2014)... , Aug. 26, 2014 Albany Molecular ... that William S. Marth , President and Chief ... Stanley Global Healthcare Conference on Monday, September 8, 2014 ... audio webcast of the presentation can be accessed at ... The webcast will be archived for 90 ...
(Date:8/26/2014)... MA (PRWEB) August 26, 2014 ... manage core research facilities , the University ... Kansas Cancer Center have chosen iLab Solutions' web-based ... effectively increase productivity. , "We are very ... and KU Cancer Center signed on with us,” ...
Breaking Biology Technology:Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2The University of Kansas Medical Center and The University of Kansas Cancer Center Select iLab Solutions Web-based Software to Streamline Operations 2The University of Kansas Medical Center and The University of Kansas Cancer Center Select iLab Solutions Web-based Software to Streamline Operations 3
... , , , For ultrafast purification of up to 750 g ... Features and benefits , , ... ultrapure DNA , ... No risk of DNA pellet loss during precipitation , ...
... , For transfection of cells with siRNA in RNAi procedures, , , ... , , , , , ... Quick and easy setup , Ready-to-use reagent , ... , , Principle , , , , , ...
... , , , , , For fast and efficient multiplex PCR , ... , , Kit Contents ... Storage and Stability , Technical Assistance , ... Limitations , Product Warranty and Satisfaction Guarantee , ...
Cached Biology Technology:HiSpeed Plasmid Kits 2TransMessenger Transfection Reagent 2TransMessenger Transfection Reagent 3QIAGEN Multiplex PCR Handbook 2QIAGEN Multiplex PCR Handbook 3QIAGEN Multiplex PCR Handbook 4QIAGEN Multiplex PCR Handbook 5QIAGEN Multiplex PCR Handbook 6QIAGEN Multiplex PCR Handbook 7QIAGEN Multiplex PCR Handbook 8QIAGEN Multiplex PCR Handbook 9QIAGEN Multiplex PCR Handbook 10QIAGEN Multiplex PCR Handbook 11QIAGEN Multiplex PCR Handbook 12QIAGEN Multiplex PCR Handbook 13QIAGEN Multiplex PCR Handbook 14QIAGEN Multiplex PCR Handbook 15QIAGEN Multiplex PCR Handbook 16QIAGEN Multiplex PCR Handbook 17QIAGEN Multiplex PCR Handbook 18QIAGEN Multiplex PCR Handbook 19QIAGEN Multiplex PCR Handbook 20QIAGEN Multiplex PCR Handbook 21QIAGEN Multiplex PCR Handbook 22QIAGEN Multiplex PCR Handbook 23QIAGEN Multiplex PCR Handbook 24QIAGEN Multiplex PCR Handbook 25QIAGEN Multiplex PCR Handbook 26QIAGEN Multiplex PCR Handbook 27QIAGEN Multiplex PCR Handbook 28QIAGEN Multiplex PCR Handbook 29QIAGEN Multiplex PCR Handbook 30QIAGEN Multiplex PCR Handbook 31QIAGEN Multiplex PCR Handbook 32QIAGEN Multiplex PCR Handbook 33
(Date:8/27/2014)... Listeria is a dreaded bacterium that can be ... last few weeks, 28 persons in Denmark have been ... in supermarkets. 13 have died. , The bacterium is ... uncanny ability to adapt to changes in its surroundings, ... Together with colleagues from the Department of Biochemistry and ...
(Date:8/27/2014)... that century-old museum specimens hold clues to how global climate ... and kill trees and the news is not good. ... oak and maple trees in warmer urban areas, which raises ... warming," says Dr. Elsa Youngsteadt, a research associate at NC ... , "More scale insects would be a problem, since scales ...
(Date:8/26/2014)... Like a protective tent over a colony of ... infections especially difficult. Microorganisms protected in a biofilm ... antibiotic resistance and recalcitrance to treatment, and biofilm-protected ... bacterial infections in humans and are 50 to ... bacterial infections. , "In essence, we may have ...
Breaking Biology News(10 mins):Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3Museum specimens, modern cities show how an insect pest will respond to climate change 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3
... Science and Technology has awarded almost $100,000 as part ... companies based in NJIT,s high technology business incubator. ... www.lenterra.com , located in NJIT,s Enterprise Development Center (EDC), ... "The Center works hard to help young inventors ...
... aromatase inhibitors to treat breast cancer or prevent its ... dietary supplement, researchers report. Genistein, a soy isoflavone ... can negate the effectiveness of aromatase inhibitors, which are ... promote tumor growth in some types of breast cancer. ...
... scientists and colleagues have completed the genome sequence and ... and destructive plant parasites - Meloidogyne hapla , ... northern root-knot nematode. The research could help lead ... the ubiquitous parasitic worm, which, along with other species ...
Cached Biology News:Exciting new companies at NJIT's small biz incubator get 100K in grants 2The dietary supplement genistein can undermine breast cancer treatment 2The dietary supplement genistein can undermine breast cancer treatment 3NC State researchers get to root of parasite genome 2NC State researchers get to root of parasite genome 3
... CyScribe GFX Purification Kit, 25 ... CyDye labeled cDNA probesProvides efficient removal ... from labeling reactions with superior yields ... for the purification of cDNA labeled ...
Detects caspase activation by flow cytometry....
Apoptosis Detection Systems and Reagents...
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
Biology Products: